Funding news - please see here for an updated statement regarding our current funding situation.

We are an international network of healthcare professionals, researchers and consumers producing systematic reviews of evidence for treating cystic fibrosis and other genetic disorders (haemoglobinopathies. coagulopathies and inborn errors of metabolism). Our editorial base is located in Liverpool, UK. 

Latest news!

Cochrane invites prospective authors to propose new Cochrane Reviews by submitting a proposal in Editorial Manager. Please see the Cochrane Library information for authors for further details.

The European Cystic Fibrosis Society (ECFS) is developing new evidence-based standards of care guidance for people with CF taking variant-specific (modulator) therapies, e.g. Kaftrio™ (Trikafta). The Cochrane Cystic Fibrosis and Genetic Disorders Group is proud to support the ECFS and collaborate on the development of this guidance, which will incorporate important published Cochrane Reviews. The document will be produced independently by international experts with no input from the pharmaceutical industry. The guidance will reflect the views and concerns of stakeholders including people with CF and their families.ECFS logo

Topics to be covered will include: eligibility for therapy; management of aspects of CF such as airway clearance and nutritional issues (which have been seen to require very different approaches after starting modulator therapy); psychological and social issues; and cost-effectiveness.

This new standards of care guidance is expected to be published in 2022. For further information, or if you wish to contribute to this project, please contact Professor Kevin Southern who is leading the committee producing the guidance.

Latest output published on The Cochrane Library
On Issue 9 2021 of The Cochrane Library we have published a total of 197 reviews and 25 protocols. There are also six registered titles currently progressing to protocol status. The production of these reviews involves a network of over 1000 contributors (authors, consumers and referees) throughout the world. We very much welcome interest from new consumers, referees and potential reviewers. Further information can be obtained by contacting the group

James Lind Alliance

By getting involved in these priority-setting partnerships you can help shape future research.

We have already successfully been involved in a priority-setting partnership for CF and you can see the results here. A second iteration of this is now being considered.

A priority-setting partnership has also been undertaken in bleeding disorders; more information can be found here.